Our Pricing

The Science Behind Mysimba Or Mounjaro

Published on: June 03, 2026

Choosing between Mysimba or Mounjaro for weight loss UK treatment depends on understanding how each medication works at a cellular level. At Cured Pharmacy, our UK-registered clinical team helps patients navigate these evidence-based options through a free online consultation, ensuring you receive the treatment best suited to your medical history and weight management goals.

How Mounjaro Works: Dual Receptor Mechanism

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK [1]. Unlike single-pathway treatments, tirzepatide simultaneously activates glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, producing complementary metabolic effects that regulate appetite, slow gastric emptying, and improve insulin sensitivity.

In the SURMOUNT-1 trial, participants receiving the 15mg maintenance dose achieved an average 22.5% body weight reduction over 72 weeks — the highest efficacy demonstrated in obesity pharmacotherapy to date [1]. The dual mechanism appears to produce greater weight loss than GLP-1-only medications, with 63% of patients achieving at least 20% weight reduction at the highest dose. Mounjaro is administered as a once-weekly subcutaneous injection, with dosing escalated gradually from 2.5mg to minimise gastrointestinal side effects.

At Cured Pharmacy, Mounjaro is available from £124.99 following assessment by a UK prescriber. The medication requires a prescription and is suitable for adults with a BMI of 30 or above, or 27 or above with weight-related comorbidities, subject to clinical approval [2].

How Mysimba Works: Central Appetite Regulation

Mysimba combines two established medications — naltrexone (an opioid receptor antagonist) and bupropion (a dopamine and noradrenaline reuptake inhibitor) — to target appetite centres in the hypothalamus and reward pathways in the mesolimbic system [3]. This dual-action oral tablet modulates neurochemical signals that control hunger, food cravings, and eating behaviour, without affecting GLP-1 or GIP receptors.

Clinical trials showed that Mysimba produced an average weight loss of 5-10% over 56 weeks when combined with lifestyle modification, with the medication working primarily through reduced caloric intake rather than metabolic changes [3]. Unlike injectable GLP-1 treatments, Mysimba is taken as two tablets twice daily, with dosing titrated over four weeks to improve tolerability. Common side effects include nausea, constipation, headache, and dizziness, typically diminishing after the first month of treatment.

Mysimba is not currently stocked at Cured Pharmacy, but our clinical team can recommend alternative oral weight loss treatments such as Orlistat (from £135.00) or injectable options like Wegovy and Saxenda. All prescription medications require assessment by a UK-registered prescriber to ensure clinical appropriateness and safety.

Comparing Mysimba or Mounjaro: Efficacy and Clinical Outcomes

Weight Loss Efficacy

Head-to-head trials directly comparing Mysimba and Mounjaro have not been conducted, but indirect evidence from separate clinical programmes provides useful context. Mounjaro demonstrated superior weight loss in the SURMOUNT trials (average 15-22.5% reduction depending on dose) compared to Mysimba's COR trials (average 5-10% reduction) [1][3]. The difference likely reflects Mounjaro's dual incretin mechanism producing both metabolic and appetite effects, whereas Mysimba works exclusively through central nervous system pathways.

For patients seeking maximal weight reduction and willing to use injectable therapy, Mounjaro typically produces greater clinical outcomes. For those preferring oral medication or with contraindications to GLP-1 treatments (such as personal or family history of medullary thyroid carcinoma), Mysimba or other oral options may be more appropriate, subject to prescriber assessment.

Administration and Practical Considerations

Injection vs Oral Therapy

Mounjaro requires a once-weekly subcutaneous injection using a pre-filled KwikPen device, which many patients find convenient compared to daily dosing schedules. The injection is administered into the abdomen, thigh, or upper arm, and most patients report minimal discomfort after initial training. Dose escalation follows a structured protocol (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg) over several months to optimise tolerability [2].

Mysimba is taken as oral tablets twice daily with food, eventually reaching a maintenance dose of two tablets twice daily (total 32mg naltrexone/360mg bupropion per day). Some patients prefer oral therapy to avoid injections, though adherence to twice-daily dosing can be challenging. The medication should not be crushed or split, and alcohol consumption should be minimised due to potential neuropsychiatric effects [3].

Side Effects and Safety Profiles

Mounjaro's most common side effects are gastrointestinal: nausea (occurring in 20-30% of patients), diarrhoea, vomiting, constipation, and abdominal discomfort [1]. These effects are typically mild to moderate, most pronounced during dose escalation, and often resolve within 4-8 weeks. Rare but serious risks include pancreatitis, gallbladder disease, and hypoglycaemia (particularly in patients taking insulin or sulfonylureas). Mounjaro is contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Mysimba's side effect profile differs significantly, with nausea, constipation, headache, dizziness, insomnia, and dry mouth reported most frequently [3]. The medication carries a black box warning in some jurisdictions regarding neuropsychiatric effects, including mood changes, depression, and suicidal ideation, particularly during the first few weeks of treatment. Mysimba is contraindicated in patients with uncontrolled hypertension, seizure disorders, eating disorders, or those taking MAO inhibitors. Blood pressure monitoring is recommended during treatment initiation.

Both medications require comprehensive medical screening before prescribing. At Cured Pharmacy, our UK prescribers review your full medical history, current medications, and contraindications during the online consultation to ensure any recommended treatment is clinically appropriate and safe for your individual circumstances.

Choosing Between Mysimba or Mounjaro for Weight Loss UK

Clinical Decision Factors

Your suitability for Mysimba or Mounjaro depends on multiple factors including BMI, weight loss goals, medical history, medication preferences, and contraindications. Patients seeking the highest efficacy weight loss and comfortable with weekly injections may be better suited to Mounjaro, while those preferring oral therapy or with contraindications to GLP-1 medications might consider Mysimba or alternatives like Orlistat.

At Cured Pharmacy, our UK-registered prescribers assess your individual clinical profile during a free online consultation taking under three minutes. We offer transparent upfront pricing on all weight loss treatments, with Mounjaro available from £124.99, Wegovy from £135.00, Saxenda from £135.00, and Orlistat from £135.00. All medications are UK-licensed, dispensed by our GPhC-registered pharmacy (9012511), and delivered in discreet packaging. Superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all clinical services to ensure the highest standards of patient safety and care.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA. https://www.gov.uk/ [accessed 13 August 2026]
3. Greenway, F. L., Fujioka, K., Plodkowski, R. A., et al. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 376(9741), 595–605. https://doi.org/10.1016/S0140-6736(10)60888-4 [accessed 13 August 2026]
4. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
5. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
6. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to lifestyle modification alongside pharmacotherapy.